| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Pachymic Acid (PA) has the ability to affect gallbladder carcinogenesis by blocking Akt and ERK signaling. Treatment with pachymic acid (PA) greatly reduced the gallbladder's Rho A, Akt, and ERK balance. Treatment with pazamic acid (PA) degrades PCNA, ICAM-1, RhoA, p-Akt, and pERK in a dose-dependent manner. Ten micrograms per milliliter of Pachymic Acid (PA) decreased cell growth twelve hours after treatment, and thirty micrograms per milliliter further suppressed cell development. Time was used to measure the rate of cell growth, and after 48 hours of treatment, poria acid (PA) at doses of 10 μg/mL, 20 μg/mL, and 30 μg/mL inhibited roughly 25%, 40%, and 70% of cell growth, respectively. Gallbladder dye development is still inhibited by pachymic acid (PA) in a dose- and time-dependent manner [1].
|
|---|---|
| ln Vivo |
Pachymic Acid (PA) anticancer activity was assessed in vivo using the NCI-H23 tumor xenograft model for human lung cancer. At doses of 30 and 60 mg/kg, Pachymic Acid (PA) effectively suppressed tumor growth for 21 days when compared with the coordinate system [2].
|
| References | |
| Additional Infomation |
Pachymic acid is a triterpenoid.
Pachymic acid has been reported in Rhodofomitopsis lilacinogilva, Fomitopsis pinicola, and other organisms with data available. See also: Smilax china root (part of). |
| Exact Mass |
528.381
|
|---|---|
| CAS # |
29070-92-6
|
| Related CAS # |
29070-92-6 CCRIS 7792
|
| PubChem CID |
5484385
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
612.2±55.0 °C at 760 mmHg
|
| Flash Point |
184.7±25.0 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
8.59
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([H])[C@]1([H])C([H])([H])[C@@]2(C([H])([H])[H])C3C([H])([H])C([H])([H])[C@@]4([H])C(C([H])([H])[H])(C([H])([H])[H])[C@]([H])(C([H])([H])C([H])([H])[C@]4(C([H])([H])[H])C=3C([H])([H])C([H])([H])[C@]2(C([H])([H])[H])[C@@]1([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])([H])C(=C([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])OC(C([H])([H])[H])=O
|
| InChi Key |
VDYCLYGKCGVBHN-DRCQUEPLSA-N
|
| InChi Code |
InChI=1S/C33H52O5/c1-19(2)20(3)10-11-22(29(36)37)28-25(35)18-33(9)24-12-13-26-30(5,6)27(38-21(4)34)15-16-31(26,7)23(24)14-17-32(28,33)8/h19,22,25-28,35H,3,10-18H2,1-2,4-9H3,(H,36,37)/t22-,25-,26+,27+,28+,31-,32-,33+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
|
| Synonyms |
Pachymic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~18.91 mM)
Ethanol : ~4.17 mg/mL (~7.89 mM) H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (1.89 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (1.89 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
